4//SEC Filing
Verwijs Marinus 4
Accession 0001415889-24-010139
CIK 0001798749other
Filed
Apr 2, 8:00 PM ET
Accepted
Apr 3, 6:00 PM ET
Size
10.9 KB
Accession
0001415889-24-010139
Insider Transaction Report
Form 4
Verwijs Marinus
Senior Vice President, CMC
Transactions
- Exercise/Conversion
Common Stock
2024-04-01$14.59/sh+5,300$77,327→ 5,300 total - Sale
Common Stock
2024-04-01$30.00/sh−1,504$45,118→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-04-01−5,300→ 79,400 totalExercise: $14.59Exp: 2032-03-20→ Common Stock (5,300 underlying) - Sale
Common Stock
2024-04-01$28.87/sh−3,796$109,579→ 1,504 total
Footnotes (4)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2023.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.475 to $29.24, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.65 to $30.45, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F4]25% of this option vested and became exercisable on March 21, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter.
Documents
Issuer
Aerovate Therapeutics, Inc.
CIK 0001798749
Entity typeother
Related Parties
1- filerCIK 0001916553
Filing Metadata
- Form type
- 4
- Filed
- Apr 2, 8:00 PM ET
- Accepted
- Apr 3, 6:00 PM ET
- Size
- 10.9 KB